Skip Navigation



Europace Advance Access published online on May 30, 2008

Europace, doi:10.1093/europace/eun136
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/8/907    most recent
eun136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lemke, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemke, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Patient-tailored implantable cardioverter defibrillator testing using the upper limit of vulnerability: the TULIP protocol

Bernd Lemke1,2,*, Thomas Lawo1, Markus Zarse2, Andrzej Lubinski3, Ulrich Kreutzer4, Johannes Mueller5, Andreas Schuchert6, Sabine Mitzenheim7, Dejan Danilovic7, Thomas Deneke on behalf of the TULIP (Threshold test using Upper Limit during ImPlantation) Study Group1

1 Department of Cardiology and Angiology, Medical Clinic II, BG University Hospital, Bergmannsheil, Bochum, Germany; 2 Department of Cardiology and Angiology, Internal Medicine Department III, Luedenscheid Clinic, Paulmannshoeher Strasse 14, D-58515 Luedenscheid, Germany; 3 Second Department of Cardiology, Medical University of Gdansk, Poland; 4 Cardiology Department, Carl-Thiem Clinic, Cottbus, Germany; 5 Cardiology Department, German Heart Centre, Berlin, Germany; 6 University Hospital Hamburg-Eppendorf, Germany; 7 Centre for Clinical Research and Scientific Studies, Biotronik GmbH & Co. KG, Hartmannstrasse 65, 91052 Erlangen, Germany

Aims: We evaluated the feasibility of the TULIP (Threshold test using Upper Limit during ImPlantation) protocol, which was designed to provide a confirmed, low defibrillation energy value during implantable cardioverter defibrillator (ICD) implantation with only two induced ventricular fibrillation (VF) episodes.

Methods and results: Ninety-eight patients (62 ± 12 years, 86 male) from 13 clinical centres underwent an active can ICD implantation. A single coupling interval derived from electrocardiogram lead II during ventricular pacing was used for VF induction shocks at 13, 11, 9, and 6 J in a step-down manner until the upper limit of VF induction (ULVI) was determined. If ULVI ≥9 J, a defibrillation energy of ULVI + 4 J was tested. For ULVI <9 J, the defibrillation test energy was 9 J. In 79/98 patients (80.6%), two induced VF episodes were sufficient to obtain confirmed defibrillation energy of 11.1 ± 3.3 J. The mean strength of the successful VF induction shock was 6.8 ± 4.3 J, the coupling interval was 303 ± 35 ms, and the number of delivered induction shocks until the first VF induction was 3.9 ± 1.6.

Conclusion: TULIP is a safe and simple device testing procedure allowing the determination of confirmed, low defibrillation energy in most patients with two VF episodes induced at a single coupling interval.

Key Words: Implantable cardioverter defibrillator, Defibrillation threshold, Upper limit of vulnerability, Ventricular fibrillation, Implantation


* Corresponding author. Tel: +49 2351 46 3326; fax: +49 2351 46 3275. E-mail address: bernd.lemke{at}rub.de

Manuscript submitted 19 November 2007. Accepted after revision 24 April 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.